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This study aims to evaluate the relation between a single measurement at baseline of body 
mass index (BMI), glycated hemoglobin (HbA1c) and subsequent clinical outcomes in patients 
with type 2 diabetes mellitus (T2DM). 
 
Method 
Patients with T2DM were recruited from an outpatient diabetes clinic in a single large teaching 
hospital in Kingston upon Hull, UK. At baseline, demographics and HbA1c were recorded. 
Patients were categorized by BMI: normal weight (18.5-24.9 kg/m2), overweight (25-29.9 
kg/m2) and obese (>30 kg/m2). Multivariable Cox regression models that included 
demographic, risk factors and comorbidities were separately constructed for all-cause, 
cardiovascular, cancer and sepsis related mortality, using four groups of HbA1c (<6%, 6.0-
6.9%, 7.0-7.9% and >8%)  
 
Results 
In total, 6220 patients with T2DM (median age 62 years, 54 % male) were followed for a 
median of 10.6 years. HbA1c levels >8.0% were associated with increased risk of all-cause 
mortality and cardiovascular death. However, this increased risk was not consistent across the 




In a large cohort of patients with T2DM elevated HbA1c levels at baseline do not consistently 
predict increased risk of all-cause and cardiovascular mortality across the different BMI 




Type 2 diabetes mellitus (T2DM) and obesity are major causes of morbidity and 
mortality worldwide.1 Obesity is a major risk factor for both diabetes and cardiovascular 
disease.2,3 
The percentage of hemoglobin that is glycated in the blood (HbA1c) is routinely used in the 
diagnosis and monitoring of patients with diabetes. Large epidemiological studies in patients 
with T2DM suggest that having either a high or a low HbA1c is associated with increased all-
cause mortality compared with HbA1c in the middle of the range.4,5 A number of factors are 
known to affect HbA1c levels, mainly time since diagnosis of diabetes, cholesterol levels and 
age.6,7   
The association between HbA1c and body weight is less clear and mainly affected by 
the interaction of different hypoglycemic treatment which can reduce HbA1c levels and cause 
either weight loss or gain.8 Whether the relationship body weight and HbA1c affects clinical 
prognostic outcomes is unclear. To our knowledge this association has never been fully 
explored, but only investigated in the context of interaction analysis between HbA1c and BMI 
to predict all-cause mortality.5,9 In particular, Van Munster et al demonstrated a significant 
interaction between HbA1c and BMI toward risk of mortality in a cohort of T2DM patients. 
9Similarly, Li et al in a subgroup analysis of their study demonstrated that higher HbA1c levels 
were associated with increased risk of mortality in obese diabetic patients.5  
The aim of our study was to assess the relationship between a single measurement at 
baseline of glycated hemoglobin (HbA1c), body mass index (BMI) and the risk of all-cause 






Patients with a diagnosis of T2DM who attended the outpatient clinic service for 
diabetes in Kingston upon Hull, UK, were enrolled in a registry between 1995 and 2005. The 
secondary diabetes service in Kingston upon Hull provided most of the care that is usually 
provided by primary care service elsewhere, particularly during the years analysed for this 
cohort. In particular, the catchment area for the diabetic service covered about 230,000 people, 
of whom an estimated 6% have been diagnosed with T2DM10. 
 Data were collected by medical and nursing staff and entered into a specifically 
designed electronic database [Angoss (Westman Medical Software, Manchester, UK)]. More 
than 99% of patients at the first visit had no known history of cardiovascular disease (CVD) 
(ischaemic heart disease, cerebrovascular, heart failure or peripheral vascular disease). Data on 
age, time since diagnosis of diabetes, smoking history, height, weight, and blood pressure were 
collected at the initial visit. Information on comorbidity (cancer, chronic obstructive pulmonary 
disease (COPD) and chronic kidney disease (CKD)) was collected at baseline.  
 
Patients were divided by BMI category as recommended by the World Health 
Organization (WHO): underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), 
overweight (25-29.9 kg/m2) and obese (>30 kg/m2).11 The cohort was followed for clinical 
events until December 2011.  
 
Ethics 
The study protocol along with all other study documentation was approved by the 




The primary outcome of the analysis was all-cause mortality. A national register 
informed the hospital of the death of any patient previously under the hospital's care regardless 
of whether the patient had left the region. In addition to all-cause mortality, the cause of death 
was obtained from the Office of National Statistics. We divided deaths as being due to: 
cardiovascular; cancer; sepsis (intended as a general term of infective illness). The secondary 
outcome was cardiovascular hospitalizations, divided into: acute coronary syndrome (ACS); 
heart failure (HF); and cerebrovascular accident (CVA). Information on hospitalizations, coded 
using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-
10-CM), and mortality was collected through the Patient Information Service of the Hull and 
East Yorkshire Hospitals National Health Service Trust, the sole hospital provider of 
emergency medical services in the region.  
 
Statistical analysis 
Results are presented as medians and interquartile ranges (IQR). Kruskal-Wallis tests 
for nonparametric data and chi square tests were used to compare continuous and dichotomous 
data, respectively, between BMI categories. 
Multivariable Cox regression models were constructed for all-cause mortality and 
cardiovascular events (ACS, CVA, or HF) using four groups of HbA1c (<6%, 6.0-6.9% 
(reference group), 7.0-7.9% and >8%). The models were adjusted for age, sex, time since 
diagnosis of diabetes, smoking history, systolic blood pressure and comorbidities that could 
have affected the body weight like COPD, cancer and CKD. If a patient had more than one 
admission for a given cause, only the first admission was included in the analysis.  Each model 
was constructed for each BMI category. We excluded underweight patients (BMI <18.5), as 
their sample size was small (only 44 patients). To check the consistency of the results we 
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performed a sensitivity analysis by assessing the outcomes in reverse by constructing each 
model for categories of HbA1c. 
All analyses were presented as hazard ratios (HR) with 95% confidence intervals (95% 
CI). A two-tailed P value less than 0.05 was considered statistically significant. Adjustment for 
multiple tests was made using the Benjamini-Hochberg procedure.  
All analyses were performed using STATA 11.0 (Stata Corp. College Station, TX, 
USA) and SPSS, 23.0 (IBM Corp. Chicago, IL, USA).  
 
Data and Resource Availability 
The data supporting the findings of this study are available from our institution as 
aggregate data, as restrictions apply to the availability to confidentiality agreements. Under 
certain circumstances, data are available from the authors upon reasonable request and with 






The cohort (Table 1) included 6,220 patients (54% men) who had a median age of 62 
(IQR 42 - 82) and were followed up for a median of 10.6 years (IQR 4.6-16.6). Only 44 
patients (0.7%) were classed as underweight, 1,354 (21.8%) patients were normal weight, 
2,316 patients (37.2%) were overweight and 2,505 (40.3%) patients were obese.  
 
Of 2,187 patients (35.2%) who died during follow-up, 946 (15.2%) died from 
cardiovascular causes, 423 (6.8%) from cancer, 527 (8.5%) were sepsis-related deaths and 291 
(4.7%) died from other causes (including pulmonary embolism and uncategorized causes). In 
addition, there were 1,305 patients hospitalized for a cardiovascular event: 535 for ACS 
(8.6%), 356 for HF (5.7%) and 414 for CVA (6.7%).  
 
Irrespective of BMI category, a baseline single measurement of HbA1c >8.0 was 
associated with increased risk of all-cause and cardiovascular mortality (HR 1.17, 95% CI: 
1.04-1.32, p=0.008) (Figure 1). However, HbA1c was not shown to significantly predict 
cardiovascular hospitalization (Figure 2). 
 
For patients with a normal BMI, an increased baseline single measurement of HbA1c 
was not associated with all-cause, cause-specific mortality (Figure 1) or hospitalization for 
ACS, HF or stroke (Figure 2).  
For patients who were overweight, a baseline single measurement of HbA1c <6.0 was 
associated with an increase in all-cause mortality (HR: 1.35, 95% CI: 1.02-1.79, p = 0.03), 
which might have been driven by an increase in sepsis-related death (HR: 1.80, 95% CI: 1.04-
3.14, p = 0.04). HbA1c >8.0 was associated with a borderline-significant increase in 
cardiovascular death (HR: 1.32, 95% CI: 1.00-1.77, p = 0.05). HbA1c was not associated with 
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an increase in cancer-related deaths (Figure 1). There was no significant association between 
HbA1c and rate of ACS, HF or stroke (Figure 2).  
Similarly to patients with normal weight, for obese patients, there was no significant 
association between HbA1c and any of the clinical outcomes  (Figures 1 and 2).  
The multiple-test procedure for type I error control gave an adjusted p <0.001 to be 
possibly considered statistically significant. Therefore, we cannot exclude that in view of 
multiple testing the statistical significant results of these studies are the result of type I error.  
Finally, as sensitivity analysis we assessed the outcomes in reverse by constructing 
each model for categories of HbA1c. This did not show a substantial difference in the results 




In a large cohort of patients with T2DM, enrolled consecutively at their first-attendance 
at a diabetes clinic, increasing HbA1c levels were not consistently associated with increased 
risk of all-cause mortality and cardiovascular death. A single baseline measurement of HbA1c 
>8.0% was associated with increased mortality only in overweight patients (BMI 25-29.9 
kg/m2). In the other weight categories (normal and obese) a trend of increased all cause and 
cardiovascular mortality was observed with a HbA1c >8.0%, although this did not reach 
statistical significance 
In our study, single baseline measurement of HbA1c did not significantly predict 
cardiovascular hospitalizations, although there was a trend of higher HbA1c levels and risk of 
CVA and HF hospitalizations.  
It is well acknowledged that higher levels of HbA1c are associated with increased 
mortality in diabetic patients, as we have confirmed in our study. 5,9,12 Previous studies have 
investigated BMI as an interacting factor with HbA1c toward prognostic outcomes.5,9 
Compared to these studies, ours is the first study that systematically investigated the prognostic 
value of HbA1c according to different weight categories for different causes of death and 
adjusting for comorbidities that could have affected the BMI. 
In view of these differences in study design, our results are not directly comparable 
with the available literature, however some consistency in the results can be observed with Li 
et al. In particular, in their subgroup analysis of a study in which they investigated the 
association of HbA1c with all-cause mortality in a T2DM population, they reported an 
increased mortality with an HbA1c >9.0% in obese patients (BMI30kg/m2).5 
Our results are consistent with those from Van Munster et al. Similarly, they investigated the 
relationship of HbA1c with cardiovascular events and mortality in a cohort of patients with 
T2DM. Similarly, they did not find a significant association between higher levels of HbA1c 
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and cardiovascular events or all-cause mortality, although they reported an interaction with 
BMI as continuous variable.9 Compared to our study, Van Munster et al had a smaller sample 
size (1753 patients) and did not have the possibility to include comorbidities in their statistical 
analysis.9 
 
 Higher HbA1c is associated with an increased risk of macrovascular and microvascular 
complications in patients with diabetes,13–15 and so a relation between HbA1c and mortality 
might be expected. We found such an association in the overweight subset of patients (BMI 
25-29.9 kg/m2). Whereas, only a trend towards increased risk of all-cause and cardiovascular 
mortality with HbA1c level >8% was observed in normal and obese patients. It could possible 
that with a bigger sample size statistical significance could have been reached. Interestingly, 
intermediate levels of glycemic control like HbA1c 7-7.9% were not associated with increased 
risk of cardiovascular hospitalizations, cardiovascular or all-cause mortality in any of the BMI 
categories. 
 
A recent systematic review reported that raised HbA1c is associated with an increase in 
cancer mortality,16 in particular pancreatic, colorectal, respiratory and gynecological cancers. 
In our study, HbA1c levels were not associated with cancer-related mortality (Figure 1), in the 
overall population and across the weight categories.  
 
In our study, the association between HbA1c <6.0 and increased risk of death amongst 
patients who were overweight was possibly driven by sepsis. In a study of patients with T2DM 
and sepsis, higher HbA1c at admission was associated with increased hospital mortality, but 
this was a very different population from ours. In our study, the link between low HbA1c and 
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increased mortality might reflect frailty, which increases the risk of sepsis and impairs recovery 
from illness.17  
 
Limitations 
          There is a risk of type II error as some of the subgroups were small. Some true 
associations between HbA1c and clinical outcome may thus have been missed due to low 
statistical power.  
We included patients only recruited before 2006 and the management of diabetes has 
subsequently changed substantially, which might have an impact on outcome.  Particularly in 
the UK, in 1996 sulphonylureas were the main treatment. However, by 2005 the use of this 
drug class had decreased substantially, and there had been an increase of treatment with 
metformin and glitazone.18 
Patients will have had different time since diagnosis of T2DM prior to referral, which 
may have affected both HbA1c and weight. We did not have information on medications, 
cholesterol levels, education or ethnicity, although our population is almost exclusively of 
European decent. We do not have information on hospitalizations outside the Hull and East 
Yorkshire Hospital Trust, but the rate of emigration from the area amongst adults is low.  
We used only measurements made at the time of referral. Treatment and the evolution 
of disease will have altered risk factors, weight and HbA1c, which may have disrupted the 
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Figure  1 - Adjusted Cox Regression analysis of HbA1c and all-cause mortality, cardiovascular 
mortality, cancer mortality and sepsis mortality. Model adjusted for age, sex, time since 
diagnosi of diabetes, smoking history, systolic blood pressure and comorbidities that could 
have affected the body weight like COPD, cancer and CKD. Abbreviations: BMI, Body Mass 
Index; CI, Confidence Interval; HR, Hazard Ratio; N, number 
 
Figure 2 - Adjusted Cox Regression analysis of HbA1c and hospitalization for ACS, CVA and 
HF. Model adjusted for age, sex, time since diagnosis of diabetes, smoking history, systolic 
blood pressure and comorbidities that could have affected the body weight like COPD, cancer 
and CKD. Abbreviations: ACS, Acute Coronary Syndrome; BMI, Body Mass Index; CI, 
Confidence Interval; CVA, Cerebrovascular Accident; HF, Heart Failure; HR, Hazard Ratio; 
N, number 
 
Supplemental Figure 1 - Adjusted Cox Regression analysis of BMI categories divided by 
HbA1c groups and all-cause mortality, cardiovascular mortality, cancer mortality and sepsis 
mortality. Model adjusted for age, sex, time since diagnosis of diabetes, smoking history, 
systolic blood pressure and comorbidities that could have affected the body weight like COPD, 
cancer and CKD. Abbreviations: BMI, Body Mass Index; CI, Confidence Interval; HR, Hazard 
Ratio; N, number 
 
Table 1 – Baseline characteristics of study population. Where not already stated results are 
shown as median (interquartile range) 
 






  <18.5 18.5-
24.9 
25-29.9 >30  
Total (n) 6220 44 1354 2316 2505 <0.001 









Men (%) 54.1 48.8 52.2 62.4d 47.6 <0.001 
Time since diagnosis of 
diabetes (years) 
2.0 (7.0) 1.5 (5.3) 4.0 
(11.0) 
2.0 (7.0) 1.0 (4.0) <0.001 
Follow up duration 
(years) 













































Smoking (%) 15.3 36.3 18.5 14.3 16.3 <0.001 
Cancer (%) 14.6 9.1 12.3 15.5 15.2 0.033 
CKD (%) 8.2 6.8 6.5 9.9 7.5 0.001 
COPD (%) 7.8 15.9 4.9 7.0 8.7 <0.001 
 
Table 1 – Baseline characteristics of study population. Where not already state results are 
shown as median (interquartile range)  
All-cause mortality 
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